2020年12月8日，Nature Cancer期刊在线发表了题为Immune-stimulating antibody conjugates elicit robust myeloidactivation and durable antitumor immunity的研究，该研究介绍了一种抗体偶联TLR7/8激动剂的技术IASC，原理相当于ADC技术。

2022年12月7日 · In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B.

TLR7/8 agonists exhibit potent antiviral activity and regulate anti-tumor immune responses. TLR7 agonists have also been used as adjuvants to improve vaccine immunogenicity and generate greater seroprotection. TLR7/8 antagonists are promising candidates for the treatment of autoimmune and inflammatory diseases.

2022年12月7日 · In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B. Keywords: Agonist; Chronic hepatitis B; Clinical trial; Immune checkpoint pathway; Toll-like receptors (TLRs); cancer immunotherapy. © 2022. The Author (s).

2021年6月9日 · Toll 样受体（Toll-like receptor，TLR）是先天免疫中一类十分重要的模式识别受体。 激活TLR，可以诱导MyD88或TRIF依赖的信号通路，激活 NF-κB，诱导细胞因子和趋化因子分泌，激活先天免疫反应和介导获得性免疫反应的激活，从而使肿瘤变热，达到重塑肿瘤微环境的 ...

Small molecule Toll-like receptor (TLR) 7/8 agonists have demonstrated potential as vaccine adjuvants, since they directly activate APCs and can enhance both humoral and cellular immune responses, especially Th1 responses. Although the natural ligands for TLR7 and TLR8 are ssRNA, the vast majority o …

TLRs 7/8 are located in the endosomal compartment and activate a specific signaling pathway in a MyD88-dependant manner. According to their involvement into various autoimmune, inflammatory and malignant diseases, researchers have designed diverse TLRs 7/8 ligands able to boost or block the inherent signal transduction.

2021年8月1日 · In addition to inducing an antiviral state through secretion of type I interferons (IFNs), synthetic TLR7/8 agonists trigger acute inflammation and stimulate adaptive immunity by activating the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway [12].

2022年12月7日 · tlr 激动剂可以通过先天性和适应性免疫反应激活 t 细胞介导的抗肿瘤反应，从而改善肿瘤治疗。 最近，已经开发出具有不同支架的TLR7或TLR8激动剂的新药物。

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin cancer treatments.